Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Faculty of Medicine, Internal Medicine Department, Division of Hematology, Istanbul University, Istanbul, Turkey.
J Chemother. 2022 May;34(3):190-198. doi: 10.1080/1120009X.2021.1976912. Epub 2021 Sep 13.
The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients' median age at BvB initiation was 33 (range: 18-76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2-11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.
对于复发或难治性（R/R）经典霍奇金淋巴瘤（cHL）患者，预后较差。 Brentuximab vedotin（Bv）和苯达莫司汀（B）联合治疗已被用作 R/R cHL 患者试验中的首选挽救方案。我们回顾性评估了 R/R cHL 患者接受 BvB 联合治疗的反应率、毒性和生存情况。在一项多中心真实世界研究中，61 例 R/R HL 患者接受静脉注射 1.8 mg/kg Bv，第 1 天和第 2 天各 90 mg/m2 B，每 21 天为一个周期，作为二线或以上挽救方案。患者接受 BvB 治疗时的中位年龄为 33 岁（范围：18-76 岁）。BvB 作为中位三线治疗，中位数治疗 4 个周期（范围：2-11）。总体反应率和完全反应率分别为 82%和 68.9%。接受 BvB 治疗后，中位随访时间为 14 个月，1 年和 2 年的总生存率分别为 85%和 72%。3/4 级毒性包括中性粒细胞减少症（24.6%）、淋巴细胞减少症（40%）、血小板减少症（13%）、贫血（13%）、输注反应（8.2%）、周围神经病变（6.5%）和其他。BvB 联合治疗可作为挽救方案，旨在为 ASCT 后复发的患者或不适合移植的患者提供桥接治疗，这些患者具有可管理的毒性特征。
